版本:
中国

BRIEF-Adamas announces publication of ADS-5102 phase 3 EASE LID clinical trial in JAMA Neurology

June 12 Adamas Pharmaceuticals Inc

* Adamas announces publication of ADS-5102 phase 3 EASE LID clinical trial in JAMA Neurology

* Adamas Pharmaceuticals Inc - new drug application for ADS-5102 currently under FDA review with August 24, 2017 PDUFA date Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐